Taiwan will expand its free pneumococcal vaccination program to include high-risk individuals aged 19 to 64 starting March 10 ...

Immune responses to PCV13 were blunted among infants who received the first vaccine dose during a respiratory viral season.

As U.S. regulatory uncertainty swirls around the vaccine space and health care in general, Vaxcyte Inc. stands poised for a ...

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 – has started pivotal trials in the prevention of both paediatric Streptococcus pneumoniae, which remains a major public health ...

For a community to be protected against contagious diseases, enough residents need to be vaccinated to provide “herd immunity ...

Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; uncertainty exists regarding the optimum PCV dosing schedule. Methods ...

The 15-valent conjugate vaccine was at least as effective ... Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 billion – with Prevnar ...

NHS England said the ‘potential’ introduction of a varicella vaccine could be launched in January 2026, subject to ‘final ...

Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Vaxcyte in a research report issued to clients and investors on Tuesday, February 25th. Leerink Partnrs ...